Across TCGA pan-cancer cohorts, ZNF816-ZNF321P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ZNF816-ZNF321P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZNF816-ZNF321P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF816-ZNF321P is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

KIRC, PAAD, and THCA are the cancer types where ZNF816-ZNF321P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF816-ZNF321P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.028	.018	3	view →
PAAD	All	All	+0.122	.046	2	view →
THCA	Female	III,IV	−0.040	.012	2	view →
COAD	Female	III,IV	−0.092	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF816-ZNF321P RNA expression & survival · all ZNF816-ZNF321P data types